Back to search

Article

Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine Dose

2022-06-29

Abstract excerpt

Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine's effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose has the capacity to neutralize SARS-CoV-2 variants in this population remains unknown. This study a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c817ecba-0759-593b-879d-4eb7584f45ac
DOI
10.20944/preprints202206.0410.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine DoseDOI 10.20944/preprints202206.0410.v1
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity
Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity
Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel DiseaseSemantic proximity
Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel DiseaseSemantic proximity
COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective StudySemantic proximity
COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine DoseSemantic proximity
Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)Semantic proximity
Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel DiseaseSemantic proximity
Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccinationSemantic proximity
Select a neighboring publication to make it the new centre.